Systemic inflammation among stable ex smokers with chronic obstructive pulmonary disease;Marcadores de inflamación sistémica en pacientes ex fumadores con enfermedad pulmonar obstructiva crónica en etapa estable

Revista Medica de Chile

Volumn 138, Issue 8, 2010, Pages 957-964

  Morales, Arturo S ^a   Dreyse, Jorge D ^b   Díaz, Orlando P ^a   Saldías, Fernando P ^a   Carrasco, Marcela ^a   Lisboa, Carmen B ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b Hospital San Juan de Dios   (Chile)

Author keywords

Chronic obstructive; Pulmonary disease; Systemic inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; INTERLEUKIN 6;

AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DYSPNEA; FEMALE; HEALTH STATUS; HUMAN; INFLAMMATION; LUNG; LUNG FUNCTION TEST; MALE; PATHOPHYSIOLOGY; QUALITY OF LIFE; REFERENCE VALUE; SMOKING CESSATION;

AGED; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; DYSPNEA; FEMALE; HEALTH STATUS; HUMANS; INFLAMMATION; INTERLEUKIN-6; LUNG; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; REFERENCE VALUES; RESPIRATORY FUNCTION TESTS; SMOKING CESSATION;

EID: 78649295765     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Global initiative for the Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. December2008http://www.goldcopd.com/Guidelineitem.
2. Maninno DM, Ford ES, Redd SC. Obstructive and restrictive lung disease and markers of inflammation in chronic obstructive pulmonary disease: data from the third National and Nutrition examination. Am J Med 2003; 114: 758-62.
3. Gan WQ, Man SPF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59: 574-80.
4. Agusti AGN, Noguera A, Sauleda J, Sala E, Pons J. Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 347-60.
5. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33:1165-85.
6. Broekhuizen R, Wouters EFM, Creutzberg EC, Scholz AMWJ. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61: 17-22.
7. Pinto-Plata VM, Mullerova H, Toso JF, Feudjo-Tapie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61: 23-8.
8. Groenewegen KH, Postma DS, Wim C Hop J, Pascal LM, Wielders L, et al. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008; 133: 350-7.
9. Pinto-Plata V, Livnat G, Girish M, Cabra, L H, Masdin, P, Linacre, P, et al Systemic Cytokines, clinical and physiological changes in patients hospitalized for exacerbations Chest 2007; 131: 37-43.
10. Parera WR, Hurst JR, Wilkinson TMA, Sapsford RJ, Müllerova H, Donaldson GC, et al. Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J 2007; 29: 527-34.
11. Walter RE, Wilk JM, Larson MG, Vasan RS, Keaney JF, lipinska I, et al. Systemic inflammation and COPD. The Framingham heart study. Chest 2008; 133: 19-25.
12. Dahl M, Vestbo J, LAnge P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175: 250-5.
13. Fogarty AW, Jones S, Britton JR, Lewis S, McKeever TC. Systemic inflammation and decline in lung function in a general population: a prospective study. Thorax 2007; 62: 515-20.
14. De Torres JP, Pinto-Plata V, Casanova C, Múllerova H, Córdoba-Lanús E, Muros de Fuentes M, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133: 1336-43.
15. Mahler DA, Wells CK. Evaluation of clinical methods for rating dyspnea. Chest 1988; 93: 580-6.
16. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-51.
17. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005; 26: 319-23.
18. Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U. S. Population. Am J Respir Crit Care Med 1999; 159: 179-87.
19. Lisboa C, Leiva A; Pinochet R, Repetto P, Borzone G, Díaz O. Valores de referencia de la capacidad inspiratoria en sujetos sanos no fumadores mayores de 50 años. Arch Bronconeumol 2007; 43: 485-9.
20. American Thoracic Society Statement. Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-7.
21. Troosters T, Gosselink S, Decramer M. Six minute walking distance in healthy elderly subjects. Eur Respir J 1999; 14: 270-4.
22. Borg GAV. Psychophysical basis of perceived exercise. Med Sci Sports Exerc 1982; 14: 337-81.
23. Celli BR, Cote CG, Marín JM, Casanova C, Montez de Oca M, Méndez RA, et al. The body-mass index, airflow obstruction, dyspnea and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-12.
24. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self complete measure for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 142: 1321-7.
25. Guyatt GH, Berman LM, Townsed M, Pugleys M, Chambers LW. A measured of quality of life for clinical trials in chronic lung disease. Thorax 1987; 47: 773-8.
26. Garrod R, Marshall J, Barley E, Fredericks S, Hagarr G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease. Primary Care Respiratory Journal 2007;16: 236-40.
27. Hurst J R, Wilkinson TMA, Perera WR, Gavin C, Donaldson GC, Wedzicha JA. Relationships among bacteria, upper airway, lower airway and systemic inflammation in COPD. Chest 2005; 127: 1219-122.
28. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BC. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease Am J Respir Crit Care Med 2001; 164: 1008-11.
29. Vernooy JH, Kucukaycan M, Jacobs JA, Chavannes NH, Buurman WA, Dentener MA, et al. Local and systemic inflammation in patients with chronic obstructive pulmonary disease: soluble tumor necrosis factor receptors are increased in sputum Am J Respir Crit Care Med 2006; 166: 1218-24.
30. Lisboa C, Dreyse J, Leiva A, Arancibia F, Saldías F, Díaz O. Oxido nítrico exhalado en condiciones estables y durante las exacerbaciones en pacientes con enfermedad pulmonar obstructiva crónica. Rev Chil Enf Respir 2009; 25: 259.
31. Agusti A. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2007; 4: 522-5.
32. Fabbri LM, Luppi F, Beghé B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31: 204-12.
33. Gan WQ, Man SFP, Sin DD. The interactions between cigarette smoking and reduced lung function on systemic inflammation. Chest 2005; 127: 558-64.
34. Sin DD, Lacy P, York E, Man SFP. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 760-5.
35. Sin DD, Man SFP, Marciniuk DD, Ford G, Fitz Gerald M, Wong E, et al. The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008; 177: 1207-14.
36. Perng D-W, Tao C-W, Su K-C, Tsai C-C, Liu L-Y, Lee Y-C. Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD. Eur Respir J 2009; 33: 778-84.